This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Padcev (enfortumab vedotin-ejfv)
General Description:
Padcev (enfortumab vedotin-ejfv) is an intravenous targeted therapy used for the second-line treatment of adults with bladder cancer and other cancers of the urinary tract. It works by delivering a cytotoxic agent directly to cancer cells expressing Nectin-4, helping to slow tumor growth and improve clinical outcomes.
Padcev is administered under the supervision of a qualified oncologist in a clinical setting. Dosage and treatment schedules are individualized based on patient condition and response.
Getting Padcev (enfortumab vedotin-ejfv) in India
Padcev is approved by the FDA (U.S.) for the treatment of urothelial carcinoma. While it may not yet be commercially available in India, patients can access it legally through a Named Patient Program (NPP) with guidance from a licensed physician.
MitoGENE assists Indian patients in obtaining Padcev safely, coordinating all regulatory approvals, import permits, and logistics to ensure a secure and compliant process.
Disease Indication:
• Urothelial Carcinoma / Bladder and Urinary Tract Cancers
Manufacturer:
Astellas Pharma Inc.
Usage:
Intravenous
Medicine Approved By:
• Food and Drug Administration (FDA)
Available Dosage Form & Package:
• Single-dose vial: 20 mg
• Single-dose vial: 30 mg
Shipping:
Cold Chain Shipping
Padcev requires cold chain shipping to protect it from heat, light, and handling. Specialized medical couriers use temperature-controlled packaging and vehicles to maintain stability and effectiveness, ensuring the medicine remains safe for patient use.
